|
Genzyme
Genzyme was an American biotechnology company based in Cambridge, Massachusetts. Since its acquisition in 2011, Genzyme (also known as Genzyme Transgenics Corp or GTC Biotherapeutics) has been a fully owned subsidiary of Sanofi. In 2010, Genzyme was the world’s third-largest biotechnology company, employing more than 11,000 people around the world. As a subsidiary of Sanofi, Genzyme has a presence in approximately 65 countries, including 17 manufacturing facilities and 9 genetic-testing laboratories. Its products are also sold in 90 countries. In 2007, Genzyme generated $3.8 billion in revenue with more than 25 products on the market. In 2006 and 2007, Genzyme was named one of ''Fortune'' magazine’s “100 Best Companies to Work for”. The company donated $83 million worth of products worldwide; in 2006, it made $11 million in cash donations. In 2005, Genzyme was awarded the National Medal of Technology, the highest level of honor awarded by the president of the United States ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Henri Termeer
Henri A. Termeer (February 28, 1946 – May 12, 2017) was a Dutch biotechnology executive and entrepreneur who is considered a pioneer in corporate strategy in the biotechnology industry for his tenure as CEO at Genzyme. Termeer created a business model adopted by many others in the biotech industry by garnering steep prices— mainly from insurers and government payers— for therapies for rare genetic disorders known as orphan diseases that mainly affect children. Genzyme uses biological processes to manufacture drugs that are not easily copied by generic-drug makers. The drugs are also protected by orphan drug acts in various countries which provides extensive protection from competition and ensures coverage by publicly funded insurers. As CEO of Genzyme from 1981 to 2011, he developed corporate strategies for growth including optimizing institutional embeddedness nurturing vast networks of influential groups and clusters: doctors, private equity, patient-groups, insurance, hea ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Integrated Genetics
Genzyme was an American biotechnology company based in Cambridge, Massachusetts. Since its acquisition in 2011, Genzyme (also known as Genzyme Transgenics Corp or GTC Biotherapeutics) has been a fully owned subsidiary of Sanofi. In 2010, Genzyme was the world’s third-largest biotechnology company, employing more than 11,000 people around the world. As a subsidiary of Sanofi, Genzyme has a presence in approximately 65 countries, including 17 manufacturing facilities and 9 genetic-testing laboratories. Its products are also sold in 90 countries. In 2007, Genzyme generated $3.8 billion in revenue with more than 25 products on the market. In 2006 and 2007, Genzyme was named one of ''Fortune'' magazine’s “100 Best Companies to Work for”. The company donated $83 million worth of products worldwide; in 2006, it made $11 million in cash donations. In 2005, Genzyme was awarded the National Medal of Technology, the highest level of honor awarded by the president of the United States ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Sheridan Snyder
Sheridan Gray Snyder OBE (born October 20, 1936) is an entrepreneur, venture capitalist, and philanthropist in the biotechnology industry. He is the founder and CEO of Biocatalyst, but also a "serial entrepreneur", a founder of Genzyme and many other companies. Snyder, who was the University of Virginia's best tennis player when he was studying for his BA in French and Romance Languages there in the 1960s, made "major contributions to the popularisation of tennis in the USA." He co-founded the National Junior Tennis League that reaches 250,000 inner-city young people and constructed a new tennis center at the University of Virginia. Beginnings Education Snyder graduated from The Lawrenceville School in New Jersey and is a 1958 graduate of The University of Virginia with a Bachelor of Arts in French & Romance Languages. At UVa, Snyder was a member of the SPE social fraternity. Snyder received an Honorary Doctorate of Law degree from the University of Dundee in 2002. Early Busin ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Sanofi
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. Originally, the corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index. Sanofi engages in the research and development, manufacturing and marketing of pharmaceutical drugs principally in the prescription market, but the firm also develops over-the-counter medication. The corporation covers seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis and vaccines (it is the world's largest producer of the latter through its subsidiary Sanofi Pasteur). History Sanofi-Synthélabo Sanofi was founded in 1973 as a subsidia ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
New England Enzyme Center
The New England Enzyme Center (NEEC) was created at the Tufts University School of Medicine in Boston, Massachusetts in 1964 as a federally supported biochemical resource center. History According to Doogab Yi, by the late 1970s NEEC had been transformed into "several commercial biotech companies." Roscoe O. Brady and his colleagues at National Institutes of Health (NIH) were almost ready for a clinical trial for an enzyme replacement therapy for Gaucher's disease that they had been working on for over a decade. They could not purify the enzyme in large enough quantities. Blair had started his career in the biotechnology industry working as a technician at Tufts medical school. In 1978 Henry E. Blair, from the NEEC and a team of researchers including Peter G. Pentchev, Roscoe O. Brady, Daniel E. Britton and Susan H. Sorrell from the National Institutes of Health co-authored a paper in the PNAS isolating and comparing enzymes in search of a treatment for Gaucher disease. In ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Cerezyme
Imiglucerase is a medication used in the treatment of Gaucher's disease. It is a recombinant DNA-produced analogue of the human enzyme β-glucocerebrosidase. Cerezyme is a freeze-dried medicine containing imiglucerase, manufactured by Genzyme Corporation. It is given intravenously after reconstitution as a treatment for Type 1 and Type 3 Gaucher's disease. It is available in formulations containing 200 or 400 units per vial. The specific activity of highly purified human enzyme is 890,000 units/mg, meanwhile the enzyme activity produced by recombinant DNA technology is approximately 40 units/mg. A typical dose is 2.5U/kg every two weeks, up to a maximum of 60 U/kg once every two weeks, and safety has been established from ages 2 and up. It is one of more expensive medications, with an annual cost of $200,000 per person in the United States. Imiglucerase has been granted orphan drug status in the United States, Australia, and Japan. Cerezyme was one of the drugs manufactured at ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Impath
Impath Inc., a New York based corporation, was a provider of cancer related laboratory services. Impath filed for bankruptcy protection in September 2003. Beginning in the late 1990s and until 2003, its business withered away, but its executives continued to talk up their stock and the profitability of their impending anti-cancer breakthroughs. In May 2004, Genzyme acquired several of Impath's laboratories and cancer-testing technologies. In September 2005 the United States Securities and Exchange Commission took action against former CEO Anuradha Saad and her colleagues, alleging fraudulent accounting. The same month Saad pleaded guilty to two counts of soliciting proxies containing false statements. It was also alleged that Saad improperly charged $120,000 in personal expenses to Impath. On Tuesday, May 30, 2006, the former president and chief operating officer of Impath, Richard P. Adelson, received a sentence from district court judge Jed S. Rakoff Jed Saul Rakoff (born Au ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Cambridge, Massachusetts
Cambridge ( ) is a city in Middlesex County, Massachusetts, United States. As part of the Boston metropolitan area, the cities population of the 2020 U.S. census was 118,403, making it the fourth most populous city in the state, behind Boston, Worcester, and Springfield. It is one of two de jure county seats of Middlesex County, although the county's executive government was abolished in 1997. Situated directly north of Boston, across the Charles River, it was named in honor of the University of Cambridge in England, once also an important center of the Puritan theology embraced by the town's founders. Harvard University, the Massachusetts Institute of Technology (MIT), Lesley University, and Hult International Business School are in Cambridge, as was Radcliffe College before it merged with Harvard. Kendall Square in Cambridge has been called "the most innovative square mile on the planet" owing to the high concentration of successful startups that have emerged in the vicinity ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Fabrazyme
α-Galactosidase ( EC 3.2.1.22, α-GAL, α-GAL A; systematic name α-D-galactoside galactohydrolase) is a glycoside hydrolase enzyme that catalyses the following reaction: : Hydrolysis of terminal, non-reducing α-D-galactose residues in α-D-galactosides, including galactose oligosaccharides, galactomannans and galactolipids It catalyzes many catabolic processes, including cleavage of glycoproteins, glycolipids, and polysaccharides. The enzyme is encoded by the ''GLA'' gene. Two recombinant forms of human α-galactosidase are called agalsidase α (INN) and agalsidase β (INN). A mold-derived form is the primary ingredient in gas relief supplements. Function This enzyme is a homodimeric glycoprotein that hydrolyses the terminal α-galactosyl moieties from glycolipids and glycoproteins. It predominantly hydrolyzes ceramide trihexoside, and it can catalyze the hydrolysis of melibiose into galactose and glucose. Reaction mechanism Disease relevance Fabry disease ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
National Medal Of Technology
The National Medal of Technology and Innovation (formerly the National Medal of Technology) is an honor granted by the President of the United States to American inventors and innovators who have made significant contributions to the development of new and important technology. The award may be granted to a specific person, to a group of people or to an entire organization or corporation. It is the highest honor the United States can confer to a US citizen for achievements related to technological progress. History The National Medal of Technology was created in 1980 by the United States Congress under the Stevenson-Wydler Technology Innovation Act. It was a bipartisan effort to foster technological innovation and the technological competitiveness of the United States in the international arena. The first National Medals of Technology were issued in 1985 by then-U.S. President Ronald Reagan to 12 individuals and one company. [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Ceredase
Alglucerase was a biopharmaceutical drug for the treatment of Gaucher's disease. It was a modified form of human β-glucocerebrosidase enzyme, where the non-reducing ends of the oligosaccharide chains have been terminated with mannose residues. Ceredase is the trade name of a citrate buffered solution of alglucerase that was manufactured by Genzyme Corporation from human placental tissue. It is given intravenously in the treatment of Type 1 Gaucher's disease. This was the first drug approved as an enzyme replacement therapy. It was approved by the FDA in 1991. It has been withdrawn from the marketFDA Prescription and Over-the-Counter Drug Product List. 32ND Edition Cumulative Supplement Number 3: March 2012. Additions/Deletions for Prescription Drug Product List/ref> due to the approval of similar drugs made with recombinant DNA technology instead of being harvested from tissue; drugs made recombinantly, since there is no concern about diseases being transmitted from the tis ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Synvisc
Hyaluronic acid (; abbreviated HA; conjugate base hyaluronate), also called hyaluronan, is an anionic, nonsulfated glycosaminoglycan distributed widely throughout connective, epithelial, and neural tissues. It is unique among glycosaminoglycans as it is non-sulfated, forms in the plasma membrane instead of the Golgi apparatus, and can be very large: human synovial HA averages about 7 million Da per molecule, or about 20,000 disaccharide monomers, while other sources mention 3–4 million Da. The average 70 kg (150 lb) person has roughly 15 grams of hyaluronan in the body, one-third of which is turned over (i.e., degraded and synthesized) per day. As one of the chief components of the extracellular matrix, it contributes significantly to cell proliferation and migration, and is involved in the progression of many malignant tumors. Hyaluronic acid is also a component of the group A streptococcal extracellular capsule, and is believed to play a role in virulen ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
